文献速递乳腺癌放疗放疗物理与技术

乳腺癌综合淋巴结光子与质子放疗后心脏毒性和复发风险的联合评估

Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-12-13

结果显示光子治疗心脏毒性风险有限,但质子治疗可进一步降低心脏毒性风险最高达2.9%、复发风险最高达0.9%,且获益与年龄相关性弱。

要点

  • 光子治疗心脏毒性风险有限,但质子治疗可进一步降低。
  • 质子治疗可降低 predicted 复发风险,个体最大降幅0.9%。
  • 质子治疗获益与患者年龄相关性弱。

核心结论

  • 现代光子治疗在多数患者中心脏毒性风险有限,但质子治疗可降低 predicted 心脏毒性风险最高达2.9%、乳腺癌复发风险最高达0.9%。
  • 质子治疗获益与年龄相关性弱。
  • 联合评估心脏暴露风险与靶区覆盖不足风险有助于理性考虑光子与质子计划的竞争性。

研究设计与样本

  • 比较质子计划采用 spot scanning 技术、单野优化、2个 en face 束。
  • 心脏毒性风险用 Darby 等模型估计。
  • 淋巴结覆盖不足的复发风险用线性剂量-反应模型估计,该模型拟合自 EORTC 22922/10925 和 NCIC-CTG MA.20 随机对照试验的复发数据。

主要发现

  • 光子治疗在 attained age 80岁时 excess absolute risk of cardiac morbidity 中位值为1.0%(范围0.2%-2.9%)伴有心脏风险因素,0.5%(范围0.03%-1.0%)不伴心脏风险因素。
  • 质子治疗相应心脏毒性风险中位值为0.13%(范围0.02%-0.5%)伴有心脏风险因素,0.06%(范围0.004%-0.3%)不伴心脏风险因素。
  • 10年后乳腺癌复发 excess absolute risk 中位值光子为0.10%(范围0.0%-0.9%),质子为0.02%(范围0.0%-0.07%)。
  • 患者年龄与质子治疗获益关联弱,Spearman 秩相关系数伴有心脏风险因素为-0.15,不伴为-0.30。

临床怎么用

  • 对于左侧乳腺癌需 comprehensive nodal 照射的患者,可联合评估心脏毒性和靶区覆盖不足的复发风险,以个体化选择光子或质子治疗计划。
  • 质子治疗可降低 predicted 心脏毒性和复发风险,但绝对获益因患者而异,需结合风险因素综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The study aims to perform joint estimation of the risk of recurrence caused by inadequate radiation dose coverage of lymph node targets and the risk of cardiac toxicity caused by radiation exposure to the heart. Delivered photon plans are compared with realistic proton plans, thereby providing evidence-based estimates of the heterogeneity of treatment effects in consecutive cases for the 2 radiation treatment modalities. METHODS AND MATERIALS: Forty-one patients referred for postlumpectomy comprehensive nodal photon irradiation for left-sided breast cancer were included. Comparative proton plans were optimized by a spot scanning technique with single-field optimization from 2 en face beams. Cardiotoxicity risk was estimated with the model of Darby et al, and risk of recurrence following a compromise of lymph node coverage was estimated by a linear dose-response model fitted to the recurrence data from the recently published EORTC (European Organisation for Research and Treatment of Cancer) 22922/10925 and NCIC-CTG (National Cancer Institute of Canada Clinical Trials Group) MA.20 randomized controlled trials. RESULTS: Excess absolute risk of cardiac morbidity was small with photon therapy at an attained age of 80 years, with median values of 1.0% (range, 0.2%-2.9%) and 0.5% (range, 0.03%-1.0%) with and without cardiac risk factors, respectively, but even lower with proton therapy (0.13% [range, 0.02%-0.5%] and 0.06% [range, 0.004%-0.3%], respectively). The median estimated excess absolute risk of breast cancer recurrence after 10 years was 0.10% (range, 0.0%-0.9%) with photons and 0.02% (range, 0.0%-0.07%) with protons. The association between age of the patient and benefit from proton therapy was weak, almost non-existing (Spearman rank correlations of -0.15 and -0.30 with and without cardiac risk factors, respectively). CONCLUSIONS: Modern photon therapy yields limited risk of cardiac toxicity in most patients, but proton therapy can reduce the predicted risk of cardiac toxicity by up to 2.9% and the risk of breast cancer recurrence by 0.9% in individual patients. Predicted benefit correlates weakly with age. Combined assessment of the risk from cardiac exposure and inadequate target coverage is desirable for rational consideration of competing photon and proton therapy plans.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Stick LB, Yu J, Maraldo MV, et al. Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2016. PMID: 28244411. doi:10.1016/j.ijrobp.2016.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。